What is Wedbush’s Estimate for APRE FY2029 Earnings?

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Stock analysts at Wedbush issued their FY2029 earnings estimates for Aprea Therapeutics in a note issued to investors on Tuesday, March 25th. Wedbush analyst R. Driscoll expects that the company will post earnings of $2.19 per share for the year. Wedbush has a “Outperform” rating and a $11.00 price objective on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share.

Separately, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research report on Wednesday, January 15th.

Aprea Therapeutics Price Performance

Shares of APRE opened at $2.20 on Thursday. The firm has a market cap of $11.96 million, a PE ratio of -0.78 and a beta of 0.82. Aprea Therapeutics has a 1 year low of $2.15 and a 1 year high of $6.80. The stock’s fifty day moving average price is $3.06 and its two-hundred day moving average price is $3.24.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.20. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.15 million.

Institutional Trading of Aprea Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in Aprea Therapeutics in the 4th quarter valued at $43,000. LPL Financial LLC purchased a new stake in shares of Aprea Therapeutics in the fourth quarter worth $53,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Aprea Therapeutics in the fourth quarter worth $116,000. Finally, Stonepine Capital Management LLC boosted its stake in Aprea Therapeutics by 8.8% during the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after buying an additional 12,047 shares during the period. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.